Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. reports developments tied to its autologous blood-based stem cell therapy platform, including VesCell™ (ACP-01), a patient-derived angiogenic cell therapy associated with ischemic and vascular-related conditions. Company news commonly covers clinical-study history, published results, FDA interactions, physician education, and commercialization activity in markets such as Florida, Canada, and The Bahamas.
Recurring updates also include private placements and other capital actions, leadership and scientific-advisory appointments, shareholder and governance matters, and regulatory planning for ACP-01 across indications including peripheral arterial disease, chronic limb threatening ischemia, angina, cardiomyopathies, congestive heart failure, and vascular dementia.
Hemostemix (OTCQB: HMTXF) announced two corporate developments: the FDA scheduled a Pre-IND meeting on January 16, 2026 to review a Phase I basket clinical trial protocol for ACP-01 covering ischemia-related indications (vascular dementia, ischemic cardiomyopathy, PAD, generalized ischemia); and the company proposed a non-brokered private placement of up to $960,000 (8,000,000 common shares at $0.12), subject to TSXV approval. All securities will have a four-month hold period. Stated use of proceeds includes FDA preparations, clinical operations expansion in Florida, The Bahamas and Canada, and general working capital.
Hemostemix (OTCQB: HMTXF) appointed Shaune Harding, OStJ, RN (non-practicing) as Director of Patient Care & Clinical Operations effective December 4, 2025. Harding will oversee patient onboarding, comprehensive medical-records transfer, multi-year health-journey mapping, continuous wearable-data monitoring (e.g., Fitbit Sense 2), monthly follow-ups, and adverse-event tracking with escalation and formal reporting.
The role covers patient programs in The Bahamas, Florida, and Canada and is described as supporting long-term continuity of care, enabling patient data capture to advance regulatory approval of ACP-01/VesCell.
Hemostemix (OTCQB: HMTXF) will present at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, highlighting clinical data for its cell therapy ACP-01/VesCell in peripheral arterial disease and chronic limb-threatening ischemia (CLTI).
Key disclosed findings include published studies reporting 83% limb salvage, 0% mortality in some cohorts, and reported ulcer size reduction from a mean of 146 mm2 to 0.48 mm2 at 3 months in treated patients. The release notes ACP-01 is available in Florida under SB 1768.
Hemostemix (OTCQB: HMTXF) will attend DFCon 2025 in San Antonio to present clinical outcomes for ACP-01 (VesCell™) and meet clinicians and researchers over three days.
Phase II midpoint results as published by the University of Toronto: 0% mortality and 83% limb preservation at a 4.5-year midpoint for treated subjects; in a subgroup with ulcers (21 treated, 8 placebo) mean ulcer size fell from 146 mm2 to 0.48 mm2 (p = 0.01) by 3 months; no treatment-related complications at one year.
Financing: TSXV approved a non-brokered private placement of $518,440 adding 520,090 units to a previously closed 4,193,000 units; each unit priced at $0.11 and includes one common share plus one warrant exercisable at $0.15 for two years, with an acceleration feature triggered if the 10-day VWAP exceeds $0.185.
Hemostemix (OTCQB: HMTXF) announced a binding Letter of Intent to acquire two cardiology practices from Dr. Roberto Fernandez-de-Castro and Dr. Hector Rosario Figueroa for 2,000,000 common shares each (subject to adjustment and TSXV approval).
The two cardiologists have combined experience treating more than 200 patients with ACP-01 across multiple cardiovascular indications, and will help implement ACP-01 therapy in the Dominican Republic and the Bahamas. Hemostemix says the acquisitions create anchor practices to accelerate commercialization and future trial expansion and to generate predictable patient flow.
The TSXV approved a financing extension to December 1, 2025. To date the company raised $461,230 via 4,193,000 Units at $0.11 per Unit; each Unit includes one share and one warrant exercisable at $0.15 for two years with an accelerated expiry clause.
Hemostemix (OTCQB: HMTXF) announced on November 20, 2025 that Dr. William R. Shankle will lead a Phase I clinical trial testing ACP-01 (VesCell) as a treatment for vascular dementia (VaD). The company described ACP-01 as its autologous stem cell therapy offered to no-option patients for various ischemic and cardiac conditions.
Dr. Shankle reportedly manages about 500 individuals diagnosed with cognitive impairment and is pre-screening up to 30 patients whose condition is primarily vascular in origin for enrolment in the trial.
Hemostemix (OTCQB: HMTXF) announced a conditionally approved non-brokered private placement of CDN$280,594.
The Offering consists of 2,244,752 common shares at CDN$0.125 per share, subject to final TSX Venture Exchange approval. The investor is arm's length to the company and not a related party.
Proceeds will be used for general working capital to support ongoing operations and business development. All securities will be subject to a four-month hold period under Canadian securities laws and any additional applicable restrictions.
Hemostemix (OTCQB: HMTXF) will present ACP-01 clinical data at the Innovations in Wound Care Conference (Dec 11–14, 2025) in Key West, Florida.
Clinical results reported include a Phase II randomized trial showing mean ulcer size fell from 146 mm2 to 0.48 mm2 (p=0.01) at 3 months, treatment-group amputation rate 4.8% vs placebo 25%, and treatment-group mortality 4.8% in that study. Hemostemix cites treatment experience across 498 subjects spanning five Phase I trials, one Phase II RCT, and one retrospective study. ACP-01 is available under Florida SB-1768. Company highlights a local non-healing wound market of $500–$600M (growing to $700–$800M) and a projected global wound care market > $20B by 2030.
Hemostemix (OTCQB: HMTXF) presented ACP-01 clinical highlights at University of Florida Grand Rounds on November 12, 2025, covering safety, efficacy signals, Florida access, and operations.
Key facts: ACP-01 is autologous, >498 treated patients with no cell-related complications reported, observed ~5% absolute LVEF increases in cardiomyopathy cohorts, +126 m 6-minute walk improvements, and a ~5% combined amputation/death rate versus ~40% historical 1-year post-amputation mortality in one dataset. ACP-01 is available in Florida under SB 1768 at a listed therapy price of US$37,000; each procedure will use IRB oversight and a 7-day production cycle.
Hemostemix (OTCQB: HMTXF) announced on November 4, 2025 that it closed the first tranche of a non-brokered private placement, raising $461,230 through issuance of 4,193,000 Units at $0.11 per Unit.
Each Unit includes one common share and one warrant exercisable at $0.15 for two years, with an accelerated expiry if the 10-day weighted average trading price exceeds $0.185 after four months. The company paid cash finder's fees of $23,698.40 and issued 215,440 Finder's Options with the same exercise price for 24 months.
Net proceeds will fund general working capital and marketing for VesCell. Certain directors participated; the company relied on exemptions under MI 61-101. Closing is subject to regulatory acceptance and securities are subject to a four-month hold.